Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy
about
Quercetin-induced ubiquitination and down-regulation of Her-2/neuNeuregulin as a heart failure therapy and mediator of reverse remodelingNeuregulin-1/erbB activities with focus on the susceptibility of the heart to anthracyclinesUse of biomarkers for the assessment of chemotherapy-induced cardiac toxicity.Coronary vasculature patterning requires a novel endothelial ErbB2 holoreceptorErbb2 is required for cardiac atrial electrical activity during developmentTwenty years of anti-HER2 therapy-associated cardiotoxicityTargets for Ibrutinib Beyond B Cell MalignanciesThe orphan adhesion-GPCR GPR126 is required for embryonic development in the mouseHeparin-binding EGF-like growth factor and ErbB signaling is essential for heart functionPotential new drug treatments for congestive heart failure.Activation of endothelial β-catenin signaling induces heart failure.Cancer therapy-induced cardiotoxicity: basic mechanisms and potential cardioprotective therapies.Actin binding GFP allows 4D in vivo imaging of myofilament dynamics in the zebrafish heart and the identification of Erbb2 signaling as a remodeling factor of myofibril architecture.Relationship between clinical data and gene expression in the HER2/ErbB2-dependent signaling pathway in patients with acute heart failure.Cardio-oncology in targeting the HER receptor family: the puzzle of different cardiotoxicities of HER2 inhibitors.Understanding, recognizing, and managing toxicities of targeted anticancer therapies.Disease candidate gene identification and prioritization using protein interaction networksAffecting Rhomboid-3 function causes a dilated heart in adult Drosophila.The art of healing broken hearts in breast cancer patients: Trastuzumab and heart failure.Gene expression in pediatric heart disease with emphasis on conotruncal defects.The transcriptomic profile of peripheral blood nuclear cells in dogs with heart failureAcute doxorubicin cardiotoxicity is associated with miR-146a-induced inhibition of the neuregulin-ErbB pathway.Mechanisms of anthracycline cardiac injury: can we identify strategies for cardioprotection?A crucial role of activin A-mediated growth hormone suppression in mouse and human heart failure.Cardiac-specific over-expression of epidermal growth factor receptor 2 (ErbB2) induces pro-survival pathways and hypertrophic cardiomyopathy in mice.The human cancer genome project--one more misstep in the war on cancer.ErbB signaling in cardiac development and disease.Developmental patterning of the cardiac atrioventricular canal by Notch and Hairy-related transcription factorsThe epidermal growth factor receptor family: biology driving targeted therapeutics.Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with [corrected] human epidermal growth factor receptor 2-positive metastatic breast cancerRecombinant neuregulin 1 does not activate cardiomyocyte DNA synthesis in normal or infarcted adult mice.Targeting ErbB3: the New RTK(id) on the Prostate Cancer Block.Rare incidence of congestive heart failure in gastrointestinal stromal tumor and other sarcoma patients receiving imatinib mesylate.Physiological, pharmacological and toxicological considerations of drug-induced structural cardiac injuryTrastuzumab alters the expression of genes essential for cardiac function and induces ultrastructural changes of cardiomyocytes in mice.Neuregulin-1β for the treatment of systolic heart failure.Pro1170 Ala polymorphism in HER2-neu is associated with risk of trastuzumab cardiotoxicityAnti-erbB2 treatment induces cardiotoxicity by interfering with cell survival pathwaysTargeted therapy in breast cancer: the HER-2/neu gene and protein.
P2860
Q24646978-EAEF1902-C40D-44E9-986D-CADC2A90E5A1Q26991903-B740E24B-51DE-41B1-A589-13A6D7A168EDQ27022965-84C12771-7C2C-421C-AF10-89B5057C0581Q27027354-01D851B8-DD2E-4F8D-B743-9DDC82ADE054Q27340378-2F3E1999-4E8D-4855-AF2E-7830875867DDQ27348830-D577DBBB-1E44-429C-90B5-4DDCD4FA8999Q28079391-1833753E-774B-4490-BF1C-3E5EAD803D25Q28087772-49940513-60A1-4A14-ABCB-6A0C1BA5A602Q28299700-703E9425-377F-4945-A403-C719C26BB48FQ28505013-B1A1CBAB-E68A-4E68-8494-E087900AEA51Q30251531-E42841A8-A5A5-4A11-B44D-70D4C4F102FDQ30383554-15C4B8B6-100F-4467-A79E-9455D1AC90AEQ30426853-4453B158-9FFF-489D-8791-F1610C2A8AA7Q30631200-365702DD-3041-46FE-9C33-76266E17045CQ30663382-560C0478-2B23-471D-B112-E88CEB5D1D2DQ33352155-417FDC09-8094-40C8-B6D8-8F1E67D54111Q33408049-3C6942D7-1F66-496B-96CB-D813DFEFB7BDQ33412922-CACBC977-FDC9-49E0-B8F8-57E779BECE68Q33594430-F13993FA-884C-45CC-BD8A-8FCF5DE40BA8Q33595716-FDF1D912-13E2-43EF-99AA-AA4B3E5D91D7Q33703791-B7201BFD-7E71-4D42-919C-F9C159BBBF87Q33883059-0FA48E42-763A-4B30-AC41-72D699F008BFQ34062716-4BD1B29C-FB2E-4E32-A847-03432E08712CQ34102834-738CEDD4-4BDE-4C29-B1C3-0B6F3E5509DFQ34116906-240AD71F-5572-4099-8901-832A7A77360CQ34388932-2188909B-0D98-47DA-A851-E0607BA2368DQ34416425-EE90340F-CD5A-43FA-AC80-42218FF6081DQ34545577-2828CC1B-0CD1-4764-B84E-EB30BBA60EE8Q34571556-76FBE360-AE0B-4E15-8B0D-7F0B8D4A7F2DQ34692233-D5C86325-55A8-4FA5-A5C5-18AE530422CBQ34775370-17470D1B-541D-4145-8047-AD0A31A746ABQ34784347-E11B4989-8950-41ED-B139-C06FD017C9C9Q34985562-E34694B6-2973-4994-A917-D6755744C419Q35012761-CFD150AB-06F6-4113-9AA7-AFE29B033762Q35039202-D6695191-6D20-4861-9BB1-D9D33EBE23BEQ35047415-C6F62680-DA73-4C9A-8F55-4C73CD34100FQ35231868-2D45CF44-DD31-4009-A52F-7922BDF11517Q35491177-5F9A1490-C8F8-47D0-AEE7-A7F9B6494888Q35605824-94928527-75E6-4640-8205-3C0F794984FDQ35648508-53747EB8-EEDB-42E5-AB4E-3A7FC3113FD1
P2860
Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy
description
2002 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունիսին հրատարակված գիտական հոդված
@hy
article publié dans les Procee ...... f the United States of America
@fr
artículu científicu espublizáu en 2002
@ast
im Juni 2002 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 2002/06/25)
@sk
vědecký článek publikovaný v roce 2002
@cs
wetenschappelijk artikel (gepubliceerd op 2002/06/25)
@nl
наукова стаття, опублікована в червні 2002
@uk
name
Conditional mutation of the Er ...... eads to dilated cardiomyopathy
@ast
Conditional mutation of the Er ...... eads to dilated cardiomyopathy
@en
Conditional mutation of the Er ...... eads to dilated cardiomyopathy
@nl
type
label
Conditional mutation of the Er ...... eads to dilated cardiomyopathy
@ast
Conditional mutation of the Er ...... eads to dilated cardiomyopathy
@en
Conditional mutation of the Er ...... eads to dilated cardiomyopathy
@nl
prefLabel
Conditional mutation of the Er ...... eads to dilated cardiomyopathy
@ast
Conditional mutation of the Er ...... eads to dilated cardiomyopathy
@en
Conditional mutation of the Er ...... eads to dilated cardiomyopathy
@nl
P2093
P2860
P3181
P356
P1476
Conditional mutation of the Er ...... eads to dilated cardiomyopathy
@en
P2093
Bernhard Pilz
Bettina Erdmann
Carmen Birchmeier
Cemil Ozcelik
Kenneth R Chien
Norbert Hübner
Stefan Britsch
P2860
P304
P3181
P356
10.1073/PNAS.122249299
P407
P577
2002-06-18T00:00:00Z